Tesamorelin vs Oxytocin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Oxytocin
Oxytocin is a natural hormone produced in the hypothalamus, often called the 'love hormone' or 'bonding hormone.' It plays key roles in social bonding, childbirth, lactation, and stress regulation.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Oxytocin |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Binds to oxytocin receptors in the brain and peripheral tissues. Promotes social bonding, reduces anxiety and stress response, and has various peripheral effects on smooth muscle contraction. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Intranasal: 20-40 IU (international units) for social/anxiolytic effects. Clinical uses (labor induction) require IV administration under medical supervision. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Intranasal spray for behavioral effects. IV only in clinical settings. Sublingual also possible. Best used situationally rather than continuously. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Intranasal: headache, nasal irritation, drowsiness. May cause over-attachment or emotional sensitivity. IV (clinical): uterine hyperstimulation, water retention. |
| Best For |